search

Sign In / Join

search

close

person Sign In / Create Account

AML News

The HealthTree News for AML is a place to learn all about AML in easy-to-understand language. The site features news articles, patient stories, AML basics articles, and clinical trial updates with new content every week.

Childhood AML - Learn About the Basics

Feb. 01, 2023

Childhood AML - Learn About the Basics

ASH 2022: Root Causes of Health Inequity

Jan. 30, 2023

ASH 2022: Root Causes of Health Inequity

ASH 2022: New Therapies in AML with Dr. Stein

Jan. 25, 2023

ASH 2022: New Therapies in AML with Dr. Stein

ASH 2022: Determining Who Does Well on Venetoclax and Azacitidine in Newly Diagnosed AML with Dr. Pollyea

Jan. 19, 2023

ASH 2022: Determining Who Does Well on Venetoclax and Azacitidine in Newly Diagnosed AML with Dr. Pollyea

ASH 2022: An Individualized Approach to Treating AML Patients with Dr. Becker

Jan. 12, 2023

ASH 2022: An Individualized Approach to Treating AML Patients with Dr. Becker

ASH 2022: Is a Restrictive Diet Necessary Post Stem Cell Transplant?

Jan. 04, 2023

ASH 2022: Is a Restrictive Diet Necessary Post Stem Cell Transplant?

What AML Taught Me in 2022

Jan. 01, 2023

What AML Taught Me in 2022

ASH 2022: A New Venetoclax Combination Therapy for Untreated AML and High-Risk MDS

Dec. 29, 2022

ASH 2022: A New Venetoclax Combination Therapy for Untreated AML and High-Risk MDS

ASH 2022: Treatment vs Quality of Life in Older AML Patients

Dec. 19, 2022

ASH 2022: Treatment vs Quality of Life in Older AML Patients

ASH 2022: Complete Response Criteria in Pediatric AML Needs Updating

Dec. 19, 2022

ASH 2022: Complete Response Criteria in Pediatric AML Needs Updating

ASH 2022: Revumenib Leads to Long-Lasting Responses in KMT2Ar(MLLr) and NPM1-Mutated AML

Dec. 14, 2022

ASH 2022: Revumenib Leads to Long-Lasting Responses in KMT2Ar(MLLr) and NPM1-Mutated AML

ASH 2022: Final Results of the VIALE-A Trial Assessing Venetoclax Plus Azacitidine

Dec. 12, 2022

ASH 2022: Final Results of the VIALE-A Trial Assessing Venetoclax Plus Azacitidine

Recent Articles

New in AML

ASH 2022: Root Causes of Health Inequity image

ASH 2022: Root Causes of Health Inequity

ASH 2022: New Therapies in AML with Dr. Stein image

ASH 2022: New Therapies in AML with Dr. Stein

ASH 2022: Determining Who Does Well on Venetoclax and Azacitidine in Newly Diagnosed AML with Dr. Pollyea image

ASH 2022: Determining Who Does Well on Venetoclax and Azacitidine in Newly Diagnosed AML with Dr. Pollyea

ASH 2022: An Individualized Approach to Treating AML Patients with Dr. Becker image

ASH 2022: An Individualized Approach to Treating AML Patients with Dr. Becker

ASH 2022: Is a Restrictive Diet Necessary Post Stem Cell Transplant? image

ASH 2022: Is a Restrictive Diet Necessary Post Stem Cell Transplant?

ASH 2022: A New Venetoclax Combination Therapy for Untreated AML and High-Risk MDS image

ASH 2022: A New Venetoclax Combination Therapy for Untreated AML and High-Risk MDS

Life With AML

Grieving the Life You Thought You'd Live After an AML Diagnosis image

Grieving the Life You Thought You'd Live After an AML Diagnosis

Transportation Assistance for AML Patients in the Tri-State Area image

Transportation Assistance for AML Patients in the Tri-State Area

Join our Adult AML Community Chapter image

Join our Adult AML Community Chapter

Inflation Reduction Act: A Battle Long & Hard Fought for Patient Cost-Savings image

Inflation Reduction Act: A Battle Long & Hard Fought for Patient Cost-Savings

HealthTree Moves for Blood Cancer Awareness Starts September 1st! image

HealthTree Moves for Blood Cancer Awareness Starts September 1st!

Managing Mouth Sores image

Managing Mouth Sores

Childhood AML

Childhood AML - Learn About the Basics image

Childhood AML - Learn About the Basics

PedAL Dare To Dream Project For Childhood AML image

PedAL Dare To Dream Project For Childhood AML

Understanding the Newly Discovered UBTF Mutation in Childhood AML image

Understanding the Newly Discovered UBTF Mutation in Childhood AML

ASH 2021: Minimizing Cardiac Toxicity in Children with Acute Myeloid Leukemia image

ASH 2021: Minimizing Cardiac Toxicity in Children with Acute Myeloid Leukemia

Targeted Therapy Using Genome Mapping for Childhood AML and Other Pediatric Cancers image

Targeted Therapy Using Genome Mapping for Childhood AML and Other Pediatric Cancers

Vyxeos Now FDA Approved for Children With Secondary AML image

Vyxeos Now FDA Approved for Children With Secondary AML

Patient Stories

articles for Patient Stories

What AML Taught Me in 2022 Blood Lines – Poetry to Celebrate Blood Cancer Awareness Month I Once Had AML, But AML Never Had Me

HealthTree

articles for HealthTree

Make a Difference This Giving Tuesday AML Round Table: What's Next if You Relapse? AML Round Table: Mid-Year Updates in AML

Clinical Trials

articles for Clinical Trials

ASH 2022: Revumenib Leads to Long-Lasting Responses in KMT2Ar(MLLr) and NPM1-Mutated AML ASH 2022: Final Results of the VIALE-A Trial Assessing Venetoclax Plus Azacitidine Partial Trial Hold Is Lifted For Take Aim Leukemia Study

HealthTree Press

articles for HealthTree Press

HealthTree Foundation Launches New Journaling Feature for Acute Myeloid Leukemia Patients The HealthTree® Foundation Unveils the First and Only Clinical Trial Finder Tool Designed Specifically for Acute Myeloid Leukemia (AML) Patients HealthTree Foundation wants to ease, demystify the clinical trial process for AML patients

Healthy Recipes

articles for Healthy Recipes

No Bake, High Calorie Energy Bites

Thanks to our HealthTree Community for AML Sponsors:

Jazz Pharmaceuticals

AbbVie

Amgen

Bristol Myers Squibb

Follow Us

Apps & Programs

Cure Hub Side Effect Solutions My Journal University Coach Connect Moves

All News

All News New in AML Life With AML Patient Stories Childhood AML Clinical Trials HealthTree HealthTree Press

Events

All Events Life With AML Treatment & Testing Research Nutrition Fitness Financial Round Tables Doctor Q&A

Round Tables

Upcoming Round Tables Past Round Tables

Podcasts

Chapters

Research

Clinical Trials

Patient Resources

AML 101 Financial Resources Find a Specialist

HealthTree Info

About HealthTree HealthTree in The News Annual Reports

Need Help?

Contact Us 1-800-930-5159

Legal Info

Terms of Use Privacy Policy

HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

Copyright © 2022 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811